Radioimmunoimaging with Mixed Monoclonal Antibodies of Nude Mice Bearing Human Lung Adenocarcinoma Xenografts

  • Duan, Dong (Department of Nuclear Medicine, the First Affiliated Hospital of Chongqing Medical University) ;
  • Li, Shao-Lin (Departments of Nuclear Medicine, the Basic Medicine of Chongqing Medical University) ;
  • Zhu, Yu-Quan (Department of Nuclear Medicine, the First Affiliated Hospital of Chongqing Medical University) ;
  • Zhang, Tao (Departments of Oncology, the First Affiliated Hospital of Chongqing Medical University) ;
  • Lei, Cheng-Ming (Department of Nuclear Medicine, the First Affiliated Hospital of Chongqing Medical University) ;
  • Cheng, Xiang-Hua (Department of Nuclear Medicine, the First Affiliated Hospital of Chongqing Medical University)
  • Published : 2012.09.30


The present study was conducted to evaluate radioimmunoimaging (RII) and in vivo distribution of mixed antibodies $^{99m}Tc$-EGFR-mAb and $^{99m}Tc$-CD44-mAb in nude mice bearing human lung adenocarcinoma xenografts. Single and mixed applications of the two radiolabeled monoclonal antibodies (mAbs) were compared. Direct labeling of $^{99m}Tc$ was applied to radiolabel the EGFR and CD44 mAbs. The properties of the radiolabeled antibodies were then characterized. RII and assessment of the distribution of the antibodies in nude mice bearing lung adenocarcinoma xenografts were achieved by applying separate and combined doses of $^{99m}Tc$-EGFR-mAb and $^{99m}Tc$-CD44-mAb. The labeling rates of $^{99m}Tc$ for EGFR-mAb and CD44-mAb were $91.5%{\pm}3.8%$ and $92.3%{\pm}4.1%$ respectively, with specific activities of 2.8 and $2.9MBq/{\mu}g$, respectively, and radiochemical purities (RCP) of 96.5% and 96.2%. The radioactivity uptake of the combined application of both radiolabeled antibodies was clearly higher than with a single application of either alone. The relative values of target-to-nontarget (T/NT) measured through the regional interest (ROI) technique were $5.59{\pm}0.42$ (mixed antibodies), $2.78{\pm}0.20$ ($^{99m}Tc$-EGFR-mAb), and $2.28{\pm}0.16$ ($^{99m}Tc$-CD44-mAb) in the RII. The body distribution of the radiolabeled antibodies and their imaging results were basically identical. Application of the mixed antibodies with $^{99m}Tc$-EGFR-mAb and $^{99m}Tc$-CD44-mAb can increase the radioactivity uptake of tumor tissue, leading to more ideal target-to-nontarget ratios, and therefore superior results.


  1. Artiko V, Petrovic M, Sobic-Saranovic D, et al (2011). Radioimmunoscintigraphy of colorectal carcinomas with 99mTc-labelled antibodies. Hepatogastroenterology, 58, 347-51.
  2. Bellomi M, Rampinelli C, Funicelli L, et al (2006). Screening for lung cancer. Cancer Imaging, 6, 9-12.
  3. Boswell CA, Brechbiel MW (2007). Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol, 34, 757-78.
  4. Cichy J, Kulig P, Pure E (2005). Regulation of the release and function of tumor cell-derived soluble CD44. Biochim Biophys Acta, 1745, 59-64.
  5. Egri G, Takáts A (2005). The immunodiagnosis of lung cancer with monoclonal antibodies. Med Sci Monit, 11, 296-300.
  6. Eren B, Sar M, Oz B (2008). MMP-2, TIMP-2 and CD44v6 Expression in Non-small-cell Lung Carcinomas. Ann Acad Med Singapore, 37, 32-9.
  7. Fritzberg AR, Abrams PG, Beaumier PL, et al (1988). Specific and stable labeling of antibodies with technetium with a diamide dithiolate chelating agent. Proc Natl Acad Sci USA, 85, 4025-9.
  8. Fukui T, Mitsudomi T (2008). Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. Gen Thorac Cardiovasc Surg, 56, 97-103.
  9. Gao SP, Mark KG, Leslie K, et al (2007). Mutations in the EGFR kinase domain me-diates STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest, 117, 3846-56.
  10. Gmeiner Stopar T, Fettich J, Zver S, et al (2008). 99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience. Nucl Med Commun, 29, 1059-65.
  11. Goldenberg DM, Chatal JF, Barbet J, et al (2007). Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther, 2, 19-31.
  12. Granville CA, Dennis PA (2005). An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol, 32, 169-76.
  13. Goldenberg DM, Sharkey RM, Paganelli G, et al (2006). Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol, 24, 823-34.
  14. Greenlee RT, M urray T, Bolden S, et al (2000). Cancer statistics 2000. CA Cancer J Clin, 50, 7-33.
  15. Hay RV, Cao B, Skinner RS, et al (2002). Radioimmunoscintigraphy of tumors autocrine for human met and hepatocyte growth factor/scatter factor. Mol Imaging, 1, 56-62.
  16. Hirsch FR, Dziadziuszko R, Thatcher N, et al (2008.) Epidermal growth factor receptor immunohistochemistry;comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer, 112, 1114-21.
  17. Ikeda K, Nomori H, Mori T, et al (2008). Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg, 85, 1430-2.
  18. Jin Y, Li JP, Tang LY, et al (2011). Protein expression and significance of VEGF, EGFR and MMP-9 in non-small cell lung carcinomas. Asian Pac J Cancer Prev, 12, 1473-6.
  19. Kwa HB, Wesseling J, Verhoeven AH, et al (1996). Immunoscintigraphy of small-cell lung cancer xenografts with anti neural cell adhesion molecule monoclonal antibody, 123C3: improvement of tumour uptake by internalisation. Br J Cancer, 73, 439-46.
  20. Lopez AD (1998). Counting the dead in China: measuring tobacco's impact in the developing world. BMJ, 317, 1399- 400.
  21. Machac J, Krynyckyi B, Kim C (2002). Peptide and antibody imaging in lung cancer. Semin Nucl Med, 32, 276-92.
  22. Malle D, Valeri RM, Phatiou C, et al (2005). Significance of immunocytochemical expression of E-cadherin, N-cadherin and CD44 in serous effusions using liquid-based cytology. Acta Cytol, 49, 11-6.
  23. Neal RD, Allgar VL, Ali N, et al (2007). Stage, survival and delays in lung, colorectal, prostate and ovarian cancer: comparison between diagnostic routes. Br J Gen Pract, 57, 212-9.
  24. Petronzelli F, Pelliccia A, Anastasi AM, et al (2005). Improved tumor targeting by combined use of two antitenascin antibodies. Clin Cancer Res, 11, 7137-45.
  25. Ren XL, Wang J, Jin BQ, et al (2001). Lung cancer radioimmunoimaging using 99Tcm-labeled anti-epidermal growth factor recepter monoclonal antibody in nude mice. Chin J Nucl Med, 21, 28-9.
  26. Rom WN, Hay JG, Lee TC, et al (2000). Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med, 16, 1355-67.
  27. Rusch V, Macapinlac H, Heelan R, et al (1993). NR-LU monoclonal antibody scanning. A helpful new adjunct to computed tomography in evaluating non-small-cell lung cancer. J Thorac Cardiovasc Surg, 106, 200-4.
  28. Sartori G, Bettelli S, Schirosi L, et al (2007). Microsatellite and EGFR, HER2 and K-RAS analyses in sclerosing hemangioma of the lung. Am J Surg Pathol, 31, 1512-20.
  29. Shi L, Wu M, Chen H (1997). Radioimmunologic targeting and therapy with antihuman primary hepatic cancer monoclonal antibodies (Hepama I) in patients. Zhonghua Zhong Liu Za Zhi, 19, 146-9.
  30. Smith-Jones PM, Pandit-Taskar N, Cao W, et al (2008). Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb. Nucl Med Biol, 35, 343-51.
  31. Tachfouti N, Belkacemi Y, Raherison C, et al (2012). First data on direct costs of lung cancer management in Morocco. Asian Pac J Cancer Prev, 35, 1813-5.

Cited by

  1. Emerging Trends for Radioimmunotherapy in Solid Tumors vol.28, pp.9, 2013,